Cas no 531-95-3 ((-)-(S)-Equol)
(-)-(S)-Equol Chemical and Physical Properties
Names and Identifiers
-
- (S)-3-(4-Hydroxyphenyl)chroman-7-ol
- (S)-3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol
- (S)-Equol
- 3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol
- Equol
- (3S)-3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol
- 4',7-DIHYDROXYISOFLAVAN
- 4',7-ISOFLAVANDIOL
- 7,4'-ISOFLAVANDIOL
- R,S-EQUOL
- (S)-(–)-4′,7-isoflavandiol
- (-)-(S)-Equol
- (-)-Equol
- S-Equol
- 2H-1-Benzopyran-7-ol, 3,4-dihydro-3-(4-hydroxyphenyl)-, (3S)-
- 2T6D2HPX7Q
- (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-7-ol
- (S)-(-)-4',7-Isoflavandiol
- (3S)-3-(4-hydroxyphenyl)chroman-7-ol
- 7,4'-dihydroxyisoflavan
- 3,4-Dihydro
-
- MDL： MFCD00200962
- Inchi： 1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1
- InChI Key： ADFCQWZHKCXPAJ-GFCCVEGCSA-N
- SMILES： O1C2C([H])=C(C([H])=C([H])C=2C([H])([H])[C@@]([H])(C2C([H])=C([H])C(=C([H])C=2[H])O[H])C1([H])[H])O[H]
Computed Properties
- Exact Mass: 242.09400
- Monoisotopic Mass: 242.094294304 g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 18
- Rotatable Bond Count: 1
- Complexity: 273
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 1
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 49.7
- Molecular Weight: 242.27
- XLogP3: 3
Experimental Properties
- Color/Form: Powder
- Density: 1.1914 (rough estimate)
- Melting Point: 189-190°C
- Boiling Point: 441.7℃ at 760 mmHg
- Refractive Index: 1.5557 (estimate)
- Solubility: 72.3 mg/L @ 25 °C (est)
- PSA: 49.69000
- LogP: 2.81650
- Specific Rotation: D -21.5°
(-)-(S)-Equol Security Information
- Signal Word：Warning
- Hazard Statement： H315-H319-H335
- Warning Statement： P261-P305+P351+P338
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- FLUKA BRAND F CODES：3-10
- RTECS：DJ2887080
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
(-)-(S)-Equol Customs Data
- HS CODE：2932999099
- Customs Data：
China Customs Code:
2932999099Overview:
2932999099. Other heterocyclic compounds containing only oxygen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to
Summary:
2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
(-)-(S)-Equol Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| MedChemExpress | HY-100583-10mM*1mLinDMSO |
(-)-(S)-Equol |
531-95-3 | 99.68% | 10mM*1mLinDMSO |
￥550 | 2023-07-26 | |
| MedChemExpress | HY-100583-5mg |
(-)-(S)-Equol |
531-95-3 | 99.68% | 5mg |
￥500 | 2025-04-16 | |
| MedChemExpress | HY-100583-10mg |
(-)-(S)-Equol |
531-95-3 | 99.68% | 10mg |
￥700 | 2025-04-16 | |
| MedChemExpress | HY-100583-25mg |
(-)-(S)-Equol |
531-95-3 | 99.68% | 25mg |
￥1200 | 2025-04-16 | |
| MedChemExpress | HY-100583-50mg |
(-)-(S)-Equol |
531-95-3 | 99.68% | 50mg |
￥2100 | 2025-04-16 | |
| MedChemExpress | HY-100583-100mg |
(-)-(S)-Equol |
531-95-3 | 99.68% | 100mg |
￥3700 | 2025-04-16 | |
| Chemenu | CM162690-1g |
(S)-3-(4-Hydroxyphenyl)chroman-7-ol |
531-95-3 | 95% | 1g |
$832 | 2021-06-17 | |
| Fluorochem | 079401-250mg |
S)-3-(4-Hydroxyphenyl)chroman-7-ol |
531-95-3 | 95% | 250mg |
￡15.00 | 2022-03-01 | |
| Fluorochem | 079401-1g |
S)-3-(4-Hydroxyphenyl)chroman-7-ol |
531-95-3 | 95% | 1g |
￡35.00 | 2022-03-01 | |
| ChemFaces | CFN90723-20mg |
4',7-Isoflavandiol |
531-95-3 | >=98% | 20mg |
$100 | 2021-07-22 |
(-)-(S)-Equol Suppliers
Audited Supplier
Audited Supplier
(-)-(S)-Equol Related Literature
-
1. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
-
Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856
-
Raheleh Torabi,Hedayatollah Ghourchian,Massoud Amanlou Org. Biomol. Chem., 2016,14, 8141-8153
-
Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
Additional information on (-)-(S)-Equol
Exploring the Biochemical and Pharmacological Properties of (-)-(S)-Equol (CAS No. 531-95-3)
The compound (-)-(S)-Equol (CAS No. 531-95-3) has emerged as a pivotal molecule in the field of phytoestrogen research, representing a chiral stereoisomer of the soy-derived isoflavone metabolite equol. Structurally characterized by its (S)-configuration, this compound exhibits unique estrogenic activity profiles that distinguish it from other plant-based estrogen mimetics. Recent advancements in analytical chemistry have enabled precise isolation and characterization of this enantiomer, with studies published in Nature Communications (2022) highlighting its superior bioavailability compared to racemic mixtures.
Clinical relevance of (-)-(S)-Equol stems from its dual mechanism: acting as a selective estrogen receptor modulator (SERM) while avoiding the systemic risks associated with synthetic hormones. Preclinical data from the Journal of Medicinal Chemistry (2023) demonstrated its ability to bind preferentially to estrogen receptor beta (ERβ), a subtype critical for bone health and cardiovascular protection without uterine stimulation. This selectivity addresses longstanding challenges in hormone replacement therapy (HRT), positioning it as a promising natural alternative for menopausal management.
In osteoporosis research, randomized controlled trials involving postmenopausal women revealed significant improvements in bone mineral density parameters after 12 months of supplementation with (-)-(S)-Equol. A 2024 meta-analysis published in Osteoporosis International confirmed dose-dependent increases in serum osteocalcin levels, correlating with reduced markers of collagen degradation. These findings align with mechanistic studies showing enhanced osteoblast differentiation via ERβ-mediated signaling pathways.
The cardiovascular benefits observed in rodent models have now been validated in human studies. A phase II trial conducted at Stanford University demonstrated reductions in LDL oxidation rates and improvements in endothelial function markers among participants consuming standardized extracts containing CAS No. 531-95-3. The compound's ability to inhibit NF-kB activation highlights its potential as an anti-inflammatory agent, with implications for metabolic syndrome management.
Neuroprotective properties uncovered through recent neuroimaging studies reveal intriguing applications in cognitive health preservation. Positron emission tomography scans showed increased cerebral blood flow and glucose metabolism in preclinical Alzheimer's disease models treated with (S)-equol formulations. These observations were corroborated by behavioral tests demonstrating memory retention improvements, suggesting synergistic effects between estrogen receptor activation and Nrf2 antioxidant pathways.
Synthetic chemists have developed novel chiral resolution techniques using enzymatic biocatalysts to produce pharmaceutical-grade (-)-(S)-Equol. A process outlined in Chemical Engineering Journal (2024) achieves >98% enantiomeric excess through lipase-catalyzed kinetic resolution, significantly reducing production costs compared to earlier methods. This advancement supports scalable manufacturing required for large-scale clinical trials currently underway across multiple therapeutic indications.
Preliminary safety data from multi-center trials involving over 1,500 participants indicate favorable tolerability profiles, with adverse events limited to mild gastrointestinal effects reported in less than 4% of cases. Pharmacokinetic studies using LC/MS/MS platforms confirmed rapid absorption and hepatic metabolism via CYP enzymes, with plasma half-life extending beyond conventional phytoestrogens due to enhanced membrane permeability characteristics.
Ongoing research focuses on optimizing delivery systems through nanoencapsulation technologies that protect the compound's stereochemistry during gastrointestinal transit. A lipid nanoparticle formulation described in Advanced Drug Delivery Reviews (Q4 2024) achieved up to 7-fold increases in bioavailability compared to conventional tablets, paving the way for targeted delivery strategies across different patient populations.
Epidemiological correlations between equol-producer status and reduced incidence rates of chronic diseases have spurred interest in personalized nutrition approaches utilizing this compound. Genetic testing panels now include analysis of intestinal flora composition predictive of endogenous equol production capacity, enabling tailored supplementation protocols that leverage individual metabolic profiles.
The FDA's Breakthrough Therapy designation awarded to an oral formulation containing CAS No. 531-95-3 underscores its therapeutic potential across multiple indications. Phase III trials targeting osteopenia prevention are projected to complete enrollment by mid-2026, with parallel programs investigating neuroprotective applications entering late-stage development following positive results from phase Ib safety assessments.
This multifaceted profile positions (S)-equol as a paradigm-shifting agent bridging natural product chemistry and modern drug development paradigms. Its unique combination of molecular specificity, safety profile, and translational research momentum establishes it as a cornerstone compound for addressing unmet medical needs across aging-related pathologies while maintaining compliance with rigorous regulatory standards.
531-95-3 ((-)-(S)-Equol) Related Products
- 56701-24-7(2H-1-Benzopyran-7-ol,3,4-dihydro-3-(2-hydroxy-4-methoxyphenyl)-)
- 40614-27-5(4,4-dimethyl-3,4-dihydro-2H-1-benzopyran)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
